Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:46 PM
Ignite Modification Date:
2025-12-24 @ 9:46 PM
NCT ID:
NCT04446832
Eligibility Criteria:
Inclusion Criteria:
* age ≥ 18 years old
* patients waiting for liver transplantation referred by hepato-gastroenterology department as part of the pre-transplant evaluation to the infectiology consultation
* patient who were informed of the study and did not object to participate
Exclusion Criteria:
* patient candidate for multi-organ transplant
* patient who received immunosuppressive therapy, biotherapy and/ or corticosteroid therapy at a dose greater than 10 mg / day of prednisone equivalent for more than 2 weeks within 3 months before vaccination (6 months of rituximab)
* patient who received polyvalent immunoglobulins within the 6 months before the serological evaluation
* patient who received systemic anti-cancer chemotherapy for solid tumor or hemopathy within 6 months preceding the start of vaccination
* splenectomized patients
* asplenic patients for a reason other than liver disease
* chronic infection with the human immunodeficiency virus (HIV)
* patient with any other hereditary immune deficiency or acquired which could compromise the vaccine response or interpretation of serological results
* patient under legal protection measure or unable to consent to the study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04446832
Study Brief:
Protocol Section:
NCT04446832